UARK 2008-01, TOTAL THERAPY 4 – A PHASE III TRIAL FOR LOW RISK MYELOMA: A RANDOMIZED TRIAL COMPARING STANDARD TOTAL THERAPY 3 (S-TT3) WITH TT3 (L-TT3)
|PI||Sarah Waheed, MD
|Purpose||This study has the following specific goals:
With this study, researchers want to find out if it will be possible to reduce some of the therapy and the way the drugs are given in an effort to reduce side effects, while still maintaining the superior results achieved with previous Total Therapy studies.
|Eligibility||You are being asked to take part in this research study because you have active multiple myeloma that requires treatment. Up to 350 research participants, male or female, age 18 or older, regardless of race or ethnicity, will take part in this study.|
|Treatment||Participants on the L-TT3 treatment will receive one course of chemotherapy during induction and consolidation phases, while participants on S-TT3 will receive two courses in each phase. In addition, participants on L-TT3 will receive a new combination (experimental) of drugs during transplant (the drug melphan in four small doses over four days in combination with three other drugs, bortezomib, thalidomide, dexamethasone), while participants on S-TT3 will receive melphalan the standard way during transplant (one large dose).|
501-526-6990 ext. 2435